Award Type: Leroy Matthews Physician-Scientist Award

Brief Program Overview/Description: The Leroy Matthews Physician-Scientist Award was established by CFF to honor and in memory of Dr. LeRoy Matthews’ dedication and commitment to CF research and care. The award is part of the Cystic Fibrosis Foundation’s Physician Training Program and is intended to encourage outstanding newly trained internists and pediatricians to enhance clinical proficiency in CF-related subspecialties and to develop the necessary research capabilities to become independent biomedical investigators.

Funding Amount: The level of support under this program ranges from $70,000 to $100,000 of direct costs per year during Phases I & II and up to $130,000 of direct costs per year during Phase III (see tables below in Section III). Awards can be made for up to 6 years, not to exceed 4 years for Phases I & II combined and not to exceed 3 years for Phase III.

Eligibility:
- Candidates must be U.S. citizens or U.S. permanent residents (must have obtained permanent residency prior to the time of application)
- Candidates for this award can be identified as early as their third year of residency training or at any time during their subspecialty training (Phases I and II). Individuals must possess an M.D., D.O., or equivalent. Those applicants that also have a Ph.D. are encouraged to apply.
- The level of effort requested for Phases I and II is commensurate with acquiring board eligibility in the subspecialty and developing proficient skills in CF related research. Phase III requires that a minimum of 75% effort be devoted to the research and research training program. The balance of effort can be devoted to other clinical and teaching pursuits only if they are consonant with the program goals.

Key Dates:
- Published: December 2, 2020
- LOI Submission Deadline: NA
- LOI Applicant Notified: NA
- Full Application Deadline: February 11, 2021
- Committee Review Date: April 2021
- Notification to Applicants: Late-May 2021
- Earliest Project Start Date: July 1, 2021

Table of Contents:
I. About the Cystic Fibrosis Foundation
II. Program and Award Overview
III. Funding Amounts
IV. Eligibility
V. Mentorship Requirements
VI. Goals of Research Currently of Interest to CFF/Priority Areas
VII. Review and Award
VIII. Submission Information
IX. Letter of Intent Guidelines
X. Full Application Guidelines
XI. Other Information
XII. Contact Information
XIII. Electronic Application Checklist
I. About the Cystic Fibrosis Foundation

The mission of the Cystic Fibrosis Foundation (CFF) is to cure cystic fibrosis (CF) and to provide all people with the disease the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care.

To achieve this mission, various types of grants and awards are offered to support meritorious research in CF.

CF Foundation Resources

The Cystic Fibrosis Foundation supports the development of a number of helpful tools and resources to assist the research community in accelerating the progress toward new scientific knowledge of and new therapies for cystic fibrosis. For more information on Tools and Resources for the CFF research community, please visit: https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/

CFF Patient Registry Data

The CF Foundation Patient Registry collects information on the health status of people with cystic fibrosis who receive care in CF Foundation-accredited care centers and agree to participate in the Registry. This information is used to create CF care guidelines, assist care teams providing care to individuals with CF, and guide quality improvement initiatives at care centers. Researchers also use the Patient Registry to study CF treatments and outcomes and to design CF clinical trials.

The Cystic Fibrosis Foundation Patient Registry is an invaluable tool for researchers who are interested in conducting studies about people with CF in the United States. About 50,000 individuals have been followed in the Registry, and many have been included for over 20 years. In addition, we recently linked the CF Foundation Patient Registry with the Pediatric Health Information System (PHIS) database. Investigators at PHIS sites can request to use these linked data. Instructions on how to request CFFPR data for your research project is included in the application instructions below.

CFF Biorepository

Cystic fibrosis biological samples are available to qualified researchers to help develop promising new studies that will support CF research and aid in drug development and drug discovery. Biorepository samples come in many different forms: blood, urine, stool, tissue, and other material. These samples are stored under appropriate conditions that ensure they are preserved for future analysis.

Since 2006, the Cystic Fibrosis Foundation has collected and stored samples from a variety of clinical trials. The CF Foundation has developed a database that combines information from these samples with data from CF clinical trials and the CF Foundation Patient Registry to create a unique and specific sample profile. Instructions on how to request CFF Biorepository samples for your research project is included in the application instructions below.

Community Voice

The CF Foundation is committed to ensuring that the CF community’s voice is heard in all of our activities. In December 2014, the CF Foundation created Community Voice, formerly known as the CF Adult and Family Advisors group, to serve as a consultative body and partner to the Foundation on various activities. Research Voice, a sub-committee within Community Voice, consists of people with CF and their family members who undergo special training on the basics of clinical research to provide insight and feedback to the research community.
Opportunities to partner with the community occur throughout the stages of a research project. Recently, several CFF funded investigator-initiated clinical research projects have utilized community engagement through Community Voice to successfully execute and complete their projects. The CF Foundation strongly encourages you to engage people with cystic fibrosis throughout the stages of clinical research. Based on your goals and objectives, the CF Foundation will work with you to determine which mechanisms are most appropriate. To learn more about how community insights can help you optimize your research project, email CommunityVoice@cff.org.

National Resource Centers

Specialized procedures are often needed to measure the outcomes of cystic fibrosis clinical trials. These include both laboratory-based measurements, such as cytology and inflammatory markers, and interpretive outcomes, such as computed tomography and nasal potential difference. For more information about National Resource Centers, please visit: https://www.cff.org/Research/Researcher-Resources/National-Resource-Centers

II. Program and Award Overview

Physician Training and Career Development Programs Overview

CF Foundation’s Physician Training & Career Development Programs (PTPs) aim to attract, develop, and retain exceptional clinicians and investigators into cystic fibrosis to address the evolving needs of the CF community. The PTPs ensure that there is a physician workforce that meets the healthcare and research needs of the CF Community by requesting applications for the 1st/2nd Year Clinical Fellowship Award, the 3rd/4th Year Clinical Fellowship Award, the 5th Year Clinical Fellowship Award, the Harry Shwachman Clinical Investigator Award (HSA), and the LeRoy Matthews Physician-Scientist Award (LMA) annually.

In 2020, 50% submitted applications were funded through the LMA. The PTP has budgeted funding for one LMA in 2021. The breakdown for 2020 funding is shown below.

<table>
<thead>
<tr>
<th>2020 PTP Award Type</th>
<th>Applications Received</th>
<th>Applications Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st/2nd Year Clinical Fellowship Award</td>
<td>31</td>
<td>27</td>
</tr>
<tr>
<td>3rd/4th Year Clinical Fellowship Award</td>
<td>28</td>
<td>17</td>
</tr>
<tr>
<td>Harry Shwachman Clinical Investigator Award</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>LeRoy Matthews Physician-Scientist Award</td>
<td>4</td>
<td>4 †</td>
</tr>
</tbody>
</table>

† Some Leroy Matthew Physician-Scientist applications funded as Clinical Fellowship Awards.

LeRoy Matthews Physician-Scientist Award Overview

The LeRoy Matthews Physician-Scientist Award was established by CFF to honor and in memory of Dr. LeRoy Matthews’ dedication and commitment to CF research and care. The award encourages outstanding newly trained internists and pediatricians to enhance clinical proficiency in CF-related subspecialties and to develop the necessary research capabilities to become independent biomedical investigators.

The award provides individuals who are either enrolled in or are about to enroll in subspecialty training with the opportunity to undertake up to six (6) years of support for their clinical training, research training, and the initiation of their research career. It is anticipated that the award will provide the opportunity for clinicians to obtain subspecialty training, to develop into independent investigators, and to initiate a research program.

The institutional environment must be one which stimulates and increases interaction between basic scientists and clinical investigators, and which indicates a strong commitment to CF research and care.
Thus, applications from domestic medical schools made on behalf of candidates will be accepted if the institution meets the following criteria:

- Have a strong, established CF-related research and clinical training program
- Have an adequate number of high-trained faculty in clinical and basic science related to CF
- Show a commitment and capability to provide guidance to clinically trained individuals in the development of independent careers as CF researchers and clinicians

**Phases** - the program and individual award application is designed in three phases, as follows:

- **Phase I: Clinical subspecialty training experience:** The first phase of the program will consist of clinical training in a subspecialty related to CF.
- **Phase II: Research training to occur during subspecialty training:** The second phase will provide the individual with the opportunity to develop skills in either basic or clinical research. Only a general research plan for Phase II is required at the time of submission if the applicant is applying during the Phase I portion of the award.
- **Phase III: Independent Research Investigation (first independent application):** The third phase is intended to provide funds for up to three years (3) for the support of independent research investigations of the recipient. This support will take place at the institution where the first academic position is obtained and need not occur at the institution where Phases I and II took place. **At least 75% of the candidate's time must be devoted to CF-related research during this phase.** The outline for this work can be submitted for consideration by CFF near the end of Phases I and II, and at the time of the first academic appointment. In addition to the scientific merit of the proposal, CFF will assess the institution's commitment to assuring the research career development of the recipient in his/her first academic appointment.

**Phases I and II can be combined,** but the combination of the two cannot exceed a period of four (4) years. At the end of this period, the person should be considered board eligible for the subspecialty for which he/she is training.

**Individuals may enter the program at any time during the Phase I or Phase II training.** However, for those individuals entering during later parts of Phases I and II, the duration of the award will be adjusted accordingly.

**The award will not be made for Phase III independently.** Other programs of CFF are available for this support. These include Research Grants, Clinical Research Awards, Pilots and Feasibility Awards, and Harry Shwachman CF Clinical Investigator Awards.

**The candidate’s progress and career goals will be subject to a periodic evaluation by CFF.** The evaluation will occur midway through Phases I and II. Awardees and their Mentors will be required to submit a special, detailed progress report midway through Phases I and II, and prior to the initiation of Phase III. The award of Phase III will be subject to an additional review by CFF, with the scientific merit of the proposed research project evaluated, as well as the institutional commitment to the career development of the candidate.

**It is desirable for individuals to complete all three phases without interruption.** It may be permissible, however, to interrupt the award and delay the start of Phase III in order to engage in further clinical or research training. In the event such a contingency arises, the awardee and the mentor must justify the interruption to CFF to assure that funds will be available to resume the award so that the candidate may complete the program.
**Award Transfers:**
Awards are made on the basis of individual and institutional merit; therefore, awards are not transferable to another trainee or institution without prior written approval from the CFF Grants and Contracts Office.

### III. Funding Amount
Funding levels are based on the phase and year when the award is made and are as follows:

<table>
<thead>
<tr>
<th>Phase I &amp; II: Subspecialty training (Fellow)</th>
<th>Stipend (salary + fringe)</th>
<th>Research*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fellowship Year 1</td>
<td>$60,000</td>
<td>$10,000</td>
<td>$70,000</td>
</tr>
<tr>
<td>Fellowship Year 2</td>
<td>$65,000</td>
<td>$10,000</td>
<td>$75,000</td>
</tr>
<tr>
<td>Fellowship Year 3</td>
<td>$80,000</td>
<td>$20,000</td>
<td>$100,000</td>
</tr>
<tr>
<td>Fellowship Year 4</td>
<td>$80,000</td>
<td>$20,000</td>
<td>$100,000</td>
</tr>
</tbody>
</table>

*Research support may include funds for technical costs, i.e. supplies, minor equipment, candidate travel to a national scientific meeting.*

The maximum level of support available under this program during Phase II is $100,000 per year.

<table>
<thead>
<tr>
<th>Phase III: Independent research (Faculty) @ 75% research effort</th>
<th>Compensation (salary + fringe)</th>
<th>Research*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty Year 1</td>
<td>$100,000</td>
<td>$30,000</td>
<td>$130,000</td>
</tr>
<tr>
<td>Faculty Year 2</td>
<td>$100,000</td>
<td>$30,000</td>
<td>$130,000</td>
</tr>
<tr>
<td>Faculty Year 3</td>
<td>$100,000</td>
<td>$30,000</td>
<td>$130,000</td>
</tr>
</tbody>
</table>

*Research support may include funds for technical costs, i.e. supplies, minor equipment, candidate travel to a national scientific meeting.*

The maximum level of support available under this program during Phase III is $130,000 per year.

**Note:** Salaries should be in compliance with institutional guidelines and can be supplemented by the Awardee Institution.

**Allowable costs include:**
- Salary and fringe benefits, not to exceed $100,000 total
- Consultant Costs
- Patient Research Costs
- Consumable research supplies
- Tuition costs up to $3,000 per year may be requested
- CF-relevant travel costs of up to $1,500 per person annually
- Minor equipment purchases under $5,000

All other costs are non-allowable without prior written approval from the CFF Grants & Contracts Office.

**Student Loan Repayment Program**
Physician Training Program Award recipients are eligible to apply for the CF Foundation’s Student Loan Repayment Program. This program offers up to $14,000 per year to offset student loan debt existing during the award period. Please refer to https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Career-Development-Awards/Student-Loan-Repayment-Program/ or contact the CFF Grants & Contracts Office for more information on this program.

### IV. Eligibility
CFF Leroy Matthews Physician-Scientist Award Policies and Guidelines
December 2020
• Candidates must be U.S. citizens or U.S. permanent residents (must have obtained permanent residency prior to the time of application).
• Candidates for this award can be identified as early as their third year of residency training or at any time during their subspecialty training (Phases I and II). Individuals must possess an M.D., D.O., or equivalent. Those applicants that also have a Ph.D. are encouraged to apply.
• Candidates should demonstrate competence in clinical activities and should show outstanding research potential. Candidates must provide evidence of serious intent for an academic research career (basic or clinical) related to CF. Please note that the review process for this award is quite competitive and highly selective.
• Candidates must be nominated by an institution on the basis of qualifications, interests, accomplishments, motivation, and potential for a research career related to CF. Evidence of the commitment of the institution to the candidate’s research and development must be provided.
• Each candidate must identify a primary Mentor who is recognized as a physician-scientist with experience in training independent investigators, and who will provide guidance for the awardee's clinical and research development. The primary Mentor must be committed to continue this involvement through the individual's total period of training (Phases I and II) under the award. The Mentor may form an advisory committee, similar to a graduate student training committee, to develop a Phase I and II program for the candidate that should include course work, seminars, initial research experience, and other educational experience necessary for intensive research in Phase II. The award does not provide financial support to the Mentor(s).
• All funds must be used on behalf of the original candidate. Individuals entering Phase III are encouraged to apply for additional research support from CFF or other funding agencies.
• The level of effort requested for Phases I and II is commensurate with acquiring board eligibility in the subspecialty and developing proficient skills in CF-related research. Phase III requires that a minimum of 75% effort be devoted to the research and research training program. The balance of effort can be devoted to other clinical and teaching pursuits only if they are consonant with the program goals.

Note: Awardees are required to inform CFF annually for a period of five years subsequent to completion of the award about academic status, publications, and research grants or contracts received. In addition, all awardees and institutions must comply with CFF award policies.

V. Mentorship Requirements
Each fellow must have a Mentor who will be responsible for the applicant’s training and research activities. Applicants are encouraged to have a either a CF Clinician or CF Researcher as part of their mentoring team.

VI. Goals of Research Currently of Interest to CFF/Priority Areas
Proposed research must be relevant to the CFF’s mission and to the health and well-being of CF patients. Applicants are encouraged, but not required, to address a research priority outlined below, and in further detail on https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Key-Research-Priorities-for-Applicants/. All applications are reviewed and scored not only on scientific merit but also on relevance to the CFF’s mission.

Research Priorities:
• Treat the underlying cause of CF for all people with the disease and drive progress toward a cure. In particular, research related to evaluating genetic-based therapies that may have clinical impact for people with CF, developing therapies that address the underlying cause of CF for individuals with nonsense and rare mutations, and novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
• Understand the biological mechanisms of, and advance new and improved treatments to address the many complications of CF, including:
  o Infections affecting people with CF;
• Lung transplant and advanced lung disease;
• Inflammation, impaired airway hydration, and mucus clearance;
• Serious complications of CF outside the lungs, such as GI complications (including in the liver, the pancreas, and the impact of nutritional deficiencies), endocrine system dysfunction (including CF related diabetes and CF bone disease);
• Mental health;
• Sinus disease;
• Sexual and reproductive health.

• Characterize the best CF care and treatment regimens to provide optimal, individualized care as the CF treatment landscape evolves
• Improve understanding of system-level and societal barriers to optimal CF care and explore opportunities to minimize their effects
• Ensure that the CF care model adapts to meet the future needs of people with CF across their lifespan

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention, and treatment strategies.

VII. Review and Award
CFF’s Physician Training Programs (PTP) Committee will evaluate all applications. The PTP Committee recommendations are reviewed by the Board of Trustees. Funding of awards is based on the priority score awarded each application and the recommendations of the PTP. Relevance of the proposed study to issues in CF is also considered in determining awards. All research awards are subject to observance of the regulations and policies of CFF related to that category of research support and are contingent upon the availability of CFF funds.

In addition to scientific merit and relevance to the CFF mission, applications will be evaluated in the following areas:

<table>
<thead>
<tr>
<th>Applicant</th>
<th>Mentor(s)</th>
<th>Environment</th>
<th>Training &amp; Research Development Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Commitment to, or intent to pursue, a research career related to CF</td>
<td>• Established expertise in CF-related research or related research areas of high priority to CF</td>
<td>• Quality (breadth and depth) of faculty in basic and/or clinical sciences related to CF at applicant institution</td>
<td>• Feasibility and impact of the proposed plan</td>
</tr>
<tr>
<td>• Potential to develop an independent research career related to CF</td>
<td>• Commitment of the Mentor for the duration of the applicant’s development and research plan</td>
<td>• Quality of institution’s CF research and training programs</td>
<td>• Didactic course work required by the applicant (if indicated)</td>
</tr>
<tr>
<td>• Research accomplishments</td>
<td>• Track record of the Mentor in training individuals for biomedical research</td>
<td>• Demonstrated interaction between basic and clinical investigators</td>
<td>• Scientific and technical merit of the proposed research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Institution’s commitment and ability to provide opportunities and facilities necessary for research career development related to CF</td>
<td>• Ability of the proposed plan to develop research skill of the applicant needed for independence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Relationship to applicant’s career development</td>
</tr>
</tbody>
</table>
| | | | • Commitment to diversity and
CFF may withdraw applications receiving low scores, and/or those deemed nonresponsive to the program announcement before the review meeting. In these cases, CFF will notify applicants if their application has been withdrawn without discussion. Applicants must address reviewer critiques in order to resubmit their applications during future application cycles.

Chief reasons for assigning low priority scores to applications during review include the following:

- Insufficient information or documentation
- Inadequate statement of hypothesis, experimental design or methods
- Failure of the applicant to demonstrate awareness of and plans for coping with key problems and pitfalls associated with the proposed research
- Insufficient or improper controls, if applicable.
- Failure of the applicant to describe potential relevance of the proposed study to issues in CF
- Failure of the applicant to document the necessary skills or training to accomplish the goals of the proposal
- Failure of the applicant to meet all criteria described in the policy statement for a given award
- Failure of the applicant to describe career goals as they may be related to a long-term commitment to CF research

VIII. Submission Information

Application Deadline: Thursday, February 11, 2021 at 5:00 PM (Eastern)

Applications must be submitted online at https://awards.cff.org
(Refer to Section X of these guidelines for specific submission instructions)

An application will be considered incomplete if it fails to comply with the instructions, or if the submitted material is insufficient to permit adequate review. CFF reviews applications electronically, and documents should be submitted online at http://awards.cff.org for review.

General Timeline:
Application Deadline _____________________________ February 11, 2021
Review _________________________________________ April 2021
Notification to Applicants _________________________ Late-May 2021
Earliest Start Date for Awarded Projects _____________ July 1, 2021

IX. Letter of Intent Guidelines

Not applicable to this RFA

X. Full Application Guidelines

Applications must be submitted online at https://awards.cff.org

Documents should be typed using:
- Font: Times New Roman 12 or Arial 11
- Margins: No less than a half inch on each side
**Note:** When all the documents have been uploaded to awards.cff.org, the system will compile them into a single PDF file. You may preview this file by selecting “Application Full Print”, as well as exporting the compiled PDF file.

To login, please visit: https://awards.cff.org

For all first-time applicants in the new Grants Management System, we ask that you pre-register to create a username and password for “http://awards.cff.org” and complete a profile well before the date you plan to submit an application. We also request that as you begin your application, you enter the title of your project, if available. If you are registered and cannot remember your password, click on the “Forgot Password?” link below the “Login” fields.

Once logged in, the award opportunities, including this Request for Applications (RFA), will be listed in the Funding Opportunities tab on the opening screen.

Locate the listing for the “Leroy Matthews Physician-Scientist Award” program. Click on the “Apply” button in the column on the far right to open the application form.

Applicants may stop at any point but must click the “Save” button at the bottom of each page before exiting in order to save their progress. When you wish to return to your draft application, please do not go through the “Funding Opportunities” tab. Instead, go to the “My Applications” tab in the right corner of the main page. When you are in the “My Applications” tab you will be able to find all your draft applications by clicking on the “Draft Applications” module.

Upon beginning the application, you will need to select the appropriate role (PI or Mentor) for who will be starting the application. Mentors will see and have access to the same application as PIs/fellows. However, the Mentor does not have the option to submit an application. **Only the PI will have the permissions to submit the application to the AIO.**

The following sections are displayed as tabs across the application screen. Click on each section and follow the directions. Click “Save” as you complete each section.

**GENERAL**

Enter the title of your project, enter the project start and end dates, select the number of periods being requested, and complete any additional questions. Also, please complete the organizational assurances indications (i.e. IRB, IACUC, and/or IBC/rDNA approval letter and status at the time of submitting the application) in this section.

*Please ensure that you review and comply with the Organizational Assurances and Certifications as cited on page 19.*

**CONTACT PROFILE**

If a profile was completed upon registration, the fields in this section will already be populated with the information entered in your Professional Profile. If you need to make any changes, you may update your profile in this section.

Once updated you must “Save and Validate” prior to returning to continue your submission.
INSTITUTION

If a profile was completed upon registration, the applicant’s/principal investigator’s institution will be pre-loaded as the Lead Institution. Domestic applicants must verify their institution by entering the Employer Identification Number (EIN) or Tax Identification Number (TIN) to search the system for the correct institution. You may find your EIN by referencing your W-9 or equivalent documentation. If the EIN/TIN is not located in our system, you have the option to add the legal institution. Please also confirm if the project site is the same as the legal institution.

Note: When choosing an institution, please select the institution where the applicant will plan to complete their fellowship. Do not choose the Institution where the applicant is completing their residency unless they are the same.

Verification of Applicant Institution’s Tax Status (upload as PDF documents):
The CFF Grants and Contracts Office must have a copy of the applicant institution’s current W-9 and 501(c)3 letter, or other documentation verifying its Federal tax status and will not issue Award Letters to Awardees if these documents are not received and on file.

• Applicants from for-profit organizations must submit a copy of the applicant institution’s W-9 and IRS documentation verifying the organization’s Federal tax status. Awards are not issued prior to having these documents on file with the CFF Grants and Contracts Office.
• Non-U.S. applicants must provide a copy of the W-8BEN-E form (required). In addition, a tax equivalency letter should be uploaded, if available. If a tax equivalency letter is not available, applicants must upload a letter stating this documentation is not available.

International Applicants (if applicable):
Applicants whose institution is not a United States based-entity will be contacted to provide additional information and completion a CFF International Institution Form. The completion of this form also includes submission of the following documentation:

• A copy of the institution’s most recent Mission Statement.
• A copy of the institution’s tax status documentation or equivalent, or a letter stating it is not available.
• A brief description of other sources of support, such as official awards, private endowments, and commercial activities, received by the institution.
• A copy of the institution’s Standard Operating Procedure(s) or relevant policy to ensure that funds provided are neither distributed to terrorists or their support networks, nor are funds used for activities that support terrorism or terrorist organizations.
• For-profit institutions must submit a complete list of key employees, members of the governing board, and/or other senior management.

Applicants who have provided these documents within the past three (3) years are not required to resubmit them. However, if any of the above documents have been updated since they were previously submitted, please upload any updated documents. The CFF Grants and Contracts Office will contact applicants if documents are outdated or missing.

*Applicants must provide English translations for all non-English documents, including material provided in support of the Research Plan.

CONTACTS

Please note: The INSTITUTION tab must be completed prior to adding internal contacts to ensure that the contacts are properly associated with the applicant institution.
Complete the required contact fields by searching by name for existing contacts at your institution for each role. If the desired institutional contact is not available in the system, you may select “Add Internal Contact” to create a basic contact profile in order to add the individual to your application.

Additional contacts not associated with the applicant institution may also be added. These contacts are considered additional contributors involved in the proposed research plan. These may include co-mentors, consultants, collaborators, or subcontractors. If the desired external contact is not available in the system, you may select “Add External Contact” to create a basic contact profile in order to add the individual to your application.

**REFERENCES**

Letters of Support and Reference are weighted heavily in the review. At least six (6) Letters of Support/Reference are required as follows:

- **The Mentor(s) for this award** – A Letter of Support from the current Mentor(s) should clearly identify the merits of the applicant and must include a description of CF-specific and other training the applicant will receive while working under the Mentor’s direction (i.e. seminars, new techniques, professional development, etc.).

- **The CF Center Director(s)** (at least one) at the applicant (or nearby) institution (if s/he is not the mentor).

- **The Chair of the applicant’s Department at the applicant institution** – The letter should clearly describe the institution’s commitment to the professional growth of the applicant.

  **Note:** If a letter from any one referee listed above fulfills two of the required roles, additional letters from references who can speak to the applicant’s scientific and clinical abilities, interests, and potential to become an independent investigator must be provided to meet the minimum requirement of six (6) letters.

- **Additional referees** – at least three (3) other individuals familiar with the candidate’s scientific interest and abilities, especially with respect to CF-related research and care, including previous preceptors and mentors. The letters of recommendation should attest to the candidate’s academic qualifications, motivation, research potential, and commitment to CF-released research and care.

Letters of Reference must be submitted prior to submission of the application. To invite Referees, go to the “REFERENCES” tab of the online application, and first search for the referee using the lookup field. If the referee is not located in the system you may select “Add Referee” to create a basic contact profile in order to add the individual to the application. Once added, this will generate automated emails (with instructions) that will be sent to each Referee. **The applicant will not be alerted when a reference is completed or declined, please make sure to check this tab regularly to see the status of the references.** The applicant should inform Referees to submit the letters at least one (1) week prior to the application deadline. This helps to ensure that the letters have been uploaded before the application is submitted. Once the application has been submitted, no documents can be added.

Letters uploaded to [http://awards.cff.org](http://awards.cff.org) should not be password protected or otherwise encrypted. Such encryption will cause errors in assembling a single-print PDF of the application. The applicant should inform the individuals writing letters to not include password protection on their documents.

**Instructions for Referees:**
When a referee logs into the system, they will need to follow these steps to access the referral request from the application:
1) Go to "External Requests" tab (highlighted in blue) on the top bar and choose the “Letters of Reference” button listed (red). See below:

![External Requests](image)

2) Once Letters of Reference is chosen, the referee will be able to click on the applicants request. They will have the choice to accept or decline.

3) If accepting, they will see the below page where they can upload their letter.

![Letter of Reference](image)

**ABSTRACTS/RELEVANCE**

In the space provided online for each abstract, provide a statement of no more than 2,000 characters (including spaces) explaining the subject of the research proposal and its relationship to CF. Two different abstracts are required, as follows:

- **Lay Abstract**: This statement will be used to inform the non-scientific departments of CFF and the general public of the nature of this work. Applicants should not include any confidential or proprietary information, including intellectual property, in the lay abstract.

- **Scientific Abstract**: This statement will be used to inform the scientific community.

  *The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, partnering with the CF community, and advancing high-quality, specialized care.*

Provide a statement of no more than 3,000 characters (including spaces) summarizing the relevance of the proposed research to the health and well-being of CF patients, for a scientific audience who may or may not have a background in the subspecialty of the proposed research.

- **Summary of Relevance to CFF mission**: All applications are reviewed and scored not only on scientific merit but also on relevance to CFF’s mission:

**BUDGET**

Select the “Edit Budget” button under Application Budget, to enter and begin completion of the application’s budget detail for each year of funding being requested. The level of support under this program ranges from $70,000 to $100,000 of direct costs per year during Phases I & II and up to $130,000 of direct costs per year during Phase III (see tables below in Section III). Awards can be made for up to 6 years, not to exceed 4 years for Phases I & II combined and not to exceed 3 years for Phase III.
Salary & Benefits - List the names and positions of all professional and non-professional personnel involved in the project, whether or not salaries are requested. Indicate the percent effort on the project for professional personnel. Personnel costs (salary and benefits) may only be requested for the applicant through this program during Phases I and II. For each individual, list dollar amounts separately for institutional base salary and fringe benefits. In accordance with National Institutes of Health (NIH) policy, salary requests may not use an institutional base salary in excess of the current federal salary cap of $197,300. Fringe benefits may be requested if they are treated consistently by the applicant institution as a direct cost to all funding agencies and foundations. Stipend levels should not exceed levels indicated below.

<table>
<thead>
<tr>
<th>Phases I &amp; II: Subspecialty training (Fellow)</th>
<th>Stipend (salary + fringe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fellowship Year 1</td>
<td>$60,000</td>
</tr>
<tr>
<td>Fellowship Year 2</td>
<td>$65,000</td>
</tr>
<tr>
<td>Fellowship Year 3</td>
<td>$80,000</td>
</tr>
<tr>
<td>Fellowship Year 4</td>
<td>$80,000</td>
</tr>
</tbody>
</table>

Consultant Costs – Give the name and institutional affiliation of any consultant who has agreed to serve in this capacity, including statisticians and physicians in connection with the project if they are not listed under personnel. In the budget justification, briefly describe services to be performed, the number of days, rate of compensation, per diem and any other associated costs.

Travel - Describe the purpose of any CF-relevant travel. Please note: expenses for travel outside the North American Continent, including travel to Hawaii, Puerto Rico, and other U.S. territories are not allowable expenses without prior written approval from the CFF Grants and Contracts Office. Travel expenses may not exceed $1,500 per person per year. Registration fees associated with conferences are in addition to this allowance should be listed under “Other Expenses”.

Patient Research Costs – Funds may be requested for patient research costs specifically related to the proposed research. The basis for estimating funds requested in this category must be justified and applicants must provide detailed information regarding the proposed costs (e.g., number of procedures, cost per procedure, ancillary costs). The scientific need for patient research costs will be considered in the review. Negotiation of these costs are between the applicant institution and the service provider.

If approved as part of the application, patient research costs are capped at the amount requested in the budget and under no circumstances is CFF responsible for any costs that are later determined non-covered by third party insurers. Applicants and applicant institutions acknowledge that CFF is solely a provider of funding for the research performed under an approved award and not a sponsor of the research as defined by the FDA (21 CFR §312.3(b)).

Consumable Supplies - Itemize supplies e.g. glassware, chemicals, animals, in separate categories and give the estimated cost of each category. If animals are involved, state the number, unit purchase cost, and unit care cost.

Other Expenses - Itemize other expenses by major categories, such as duplication costs, tuition costs (not to exceed $3,000), publication costs, minor equipment items under $5,000, conference registration fees, etc.

FULL APPLICATION UPLOADS
Download the available templates applicable to the project, upload the completed templates to the corresponding attachment types within this section. Templates available for download include:
• Biographical Sketches for Key Personnel
• Mentor’s Results of Past and Current CFF/CFFT Support
• Applicant’s Results of Past and Current CFF/CFFT Support
• Other Support
• Facilities Available
• Budget Justification
• Research Plan
• Data Safety Monitoring Plan (if applicable)
• Training Plan
• CF-Related Activities of the Mentor and the Applicant Institution
• Critique Response (if resubmission)
• Names and Addresses of References

Biographical Sketches for Key Personnel
Complete and upload an NIH Biographical Sketch for all key project personnel, beginning with the Applicant/Principal Investigator. International applicants can upload a biosketch that is equivalent in content to the NIH template provided. (CFF defines “key personnel” as any individual with an advanced degree that will play an instrumental role in the accomplishment of the research project.) Do not exceed five (5) pages per person.

Mentor’s Results of Past and Current CFF/CFFT Support
Mentors are requested to identify the results of past and current CFF/CFFT support (e.g., subsequent funding from other sources, journal articles, and invited presentations) and the CFF/CFFT grant/award from which they resulted for the past three to five years. Please note that the following information must be included with each research project identified:
• CFF/CFFT Account #
• Principal Investigator (PI)
• CFF/CFFT Project Title
• Applicant’s Title on Project
• Project Start/End Dates
• Total CFF/CFFT Award Amount
• Results of Support

Applicant’s Results of Past and Current CFF/CFFT Support
Applicants are also requested to identify the results of past and current CFF/CFFT support in the same manner indicated for the Mentor(s) above.

Other Support
Complete and upload the Other Support form for all key project personnel, beginning with the Applicant/Principal Investigator. There is no page limitation. Information on other support assists CFF in the identification and resolution of potential sources of overlap. Scientific and budgetary overlap should be minimized. Commitment of an individual’s effort greater than 100 percent, is not permitted.

Facilities Available
Not applicable to applicants applying only for the first year of the fellowship. Describe the facilities and equipment available at the applicant’s institution that will be used for this project, such as laboratory, clinical, animal, computer, office, etc. Provide any additional information about the environment, including any support services available that will be utilized. Describe their pertinent capabilities, proximity and anticipated extent of use. If facilities or equipment at a consultant’s or
collaborative site will be used, they should be identified and clearly described. There is no page limit. Use continuation pages, if necessary.

**Budget Justification**
Describe costs listed in the Budget Detail. Use major categories, such as Salary & Benefits, Consultant Costs, Major Equipment, etc. Justify all items and make sure amounts and figures listed in the narrative are consistent with those listed in the Budget Detail.

**Research Plan**
- Key figures and legends must be included in the Research Plan and should be of sufficient quality and size to be evaluated by the reviewer. If uploaded as Appendices, they will NOT be reviewed.
- At the top of each page, type the Principal Investigator’s name. Each page must be sequentially numbered at the bottom.
- Page limit: Ten (10) single-sided pages, not including the Literature Cited. Applications exceeding this page limit will not be reviewed. Include sufficient information to permit effective review without reference to previous applications. Information should be presented in a clear and concise manner, while being specific and informative.

If your application is a resubmission of an earlier one, your revisions should be clearly indicated by a change in font, bolded or underlined. CFF will not review resubmissions that have not been revised.

**Note:** If applicants plan to conduct clinical research during their fellowship training, special attention should be given to Section ‘d’ of the Research Plan (Experimental Design and Methods for Clinical Research only) and, for studies that place human subjects at more than minimal risk, to the completion of the Data Safety Monitoring Plan (DSMP).

a. **Hypothesis and Specific Aims:** State concisely and realistically the intent of the proposed research and the hypothesis to be tested. The specific aims should be relevant to the mission of the Cystic Fibrosis Foundation. Do not exceed one page.
b. **Background and Significance:** Briefly describe the background. Critically evaluate existing knowledge and specifically identify the gaps that the project is intended to fill. Concisely state the importance and rationale of this research by relating the specific aims to longer-term objectives. This section should also show the potential importance of the proposed work to CF, in particular in those areas listed as areas of special interest to CFF. In addition, describe the relationship of the proposed work to your long-term career goals. Preference will be given to applicants who express an interest in a long-term career in CF-related research.
c. **Preliminary Results:** If applicable, provide a detailed discussion of any preliminary results.
d. **Experimental Design and Methods:**
   For applicants proposing to carry out Basic Research through this support mechanism:
   Provide a detailed discussion of the experimental design and methods to be used to accomplish the specific aims. Describe the protocols, including methods for new techniques, and explain potential advantages over existing methodologies. Discuss the data expected to be obtained and the means by which data will be analyzed and interpreted. If human subjects are involved, provide details of the methods for patient selection and care. Discuss potential difficulties and/or limitations of the proposed procedures and alternative approaches to achieve aims. Point out any procedures, situations or materials that may be hazardous to personnel or patients and the precautions to be exercised.

   For applicants proposing to carry out Clinical Research through this support mechanism:
   Provide a detailed discussion of the experimental design and procedures to be used to accomplish specific aims. Please discuss: study hypothesis; primary and secondary outcome
measures; study sample-inclusion and exclusion criteria; sample size estimates*; subject enrollment including age range; puberty status; gender distribution; randomization scheme if applicable; description of experimental procedures and schedule including a study time-line; drugs and dosage; measures of compliance; follow-up schedule including a study time-line for full project up to three years; efficacy and safety evaluation, data monitoring and quality control; and a description of your proposed data analysis and statistical procedures for your hypothesis testing. Although no page limit is specified for this section, make every attempt to be concise and succinct.

*For sample size estimates, please provide all estimates of means, standard deviations, rates or proportions used to calculate each of your sample size or power estimates. Please include in the statistical section whether you will use a one or two-tailed test, the power selected for such a test (if making a sample size calculation), and the reference for your sample size or power calculation. In instances of pilot studies where some of these parameters are unknown, we will accept your best estimates of the unknown parameters if preliminary data are not available, and if your calculation is a preliminary estimate before formal sample size can be calculated for a larger study. Please identify if you are making estimates from data or from personal estimates. This section must document access to adequate numbers of subjects.

Discuss the potential difficulties and limitations of the proposed procedures and alternative strategies for achieving the aims. If the Mentor(s) is not a CF Center Director or Co-Director, a letter of support from the Center Director is required.

e. Literature Cited: References should be numbered in the sequence that they appear in the text and listed at the end of the Research Plan. Each citation must include the names of authors, the name of the journal or book, volume number, page number and year of publication (titles are optional).

Data Safety Monitoring Plan (if applicable)

*For clinical research projects only

In compliance with Federal regulations, applicants whose proposed study places human subjects at more than minimal risk must submit a general description of the Data Safety Monitoring Plan (DSMP). A DSMP helps to ensure subject safety, as well the validity and integrity of the data. Furthermore, a DSMP allows for the monitoring of study data to assess whether or not an early termination is necessary for safety or efficacy reasons.

The extent of monitoring required for a study is dependent on the level of risk involved for the subjects, as well as the size and complexity of the study. Large, multi-center CFF-funded interventional clinical trials must utilize a Data Safety and Monitoring Board (DSMB). In addition, CFF may require that investigators utilize the CFF DSMB for any other interventional CF clinical trial that meets one or more of the following criteria:

- Multi-center;
- Randomized;
- Conducted in an emergency setting;
- Use high-risk interventions, such as gene therapy or gene transfer; or
- Include particularly vulnerable study populations, such as pediatric patients.

Note: On the available template, please check whether a DSMP is required and upload the template regardless of the response.

Address the following areas in the DSMP:
Assessment of Risk – Describe the level of risk the proposed research presents to subject participants and provide a detailed justification for the level of risk. Discuss who will monitor the study.

Level of Risk
- Minimal Risk
  - Study poses no more risk than expected in daily life (blood draw, physical exam, etc.)
  - Observational studies
  - Survey or questionnaire studies
- Low Risk
  - Post-marketing study Phase IV drug or device, as defined by FDA
- Moderate Risk
  - Substantial risk (>5%) of a Serious Adverse Event (SAE) originating from the underlying condition of the enrolled subject
  - Phase I or II study with available safety data in humans
- High Risk
  - Involves an intervention or invasive procedure with substantial risk
  - Involves the use of a new chemical or drug for which there is little or no toxicology data in humans
  - A gene therapy study or research involving recombinant DNA molecules (gene transfer)
  - Involves vulnerable populations (pediatric, pregnant, etc.)

Anticipated Adverse Events and Grading Scale – Describe anticipated adverse events (AEs), including expected frequency and the grading scale to be used. Discuss plans for addressing AEs.

Reporting of AEs – Detail the plan for reporting AEs, including who shall be notified in the event an AE should occur.

Safety Monitoring Plan – Describe all tests, evaluations, and exclusion criteria that will be implemented to ensure and monitor the safety of human subjects. Discuss plans for stopping the study if necessary.

Safety Reviews – Describe the process for monitoring and reviewing subject safety data, including the frequency of such reviews. Include details as to who will perform the monitoring and plans for reporting. If this information is not available at the time of submission of the application, note that CFF will not release awarded payments until it is provided.

 Registrations for Investigator-Initiated Clinical Trials:
- Clinicaltrials.gov (United States): Applicants are required to register all non-exempt human subject studies in the ClinicalTrials.gov database to ensure information is freely available on CFF-funded trials within the community. The registration should be no later than twenty-one (21) days after the first subject is enrolled. CFF requires copies of documentation confirming this registration, when applicable.

CFF Patient Registry Data Request (if applicable)

Researchers who wish to request Registry data for their proposed research study must complete and submit the “Application for CFFPR Data and Confidentiality Agreement” application to datarequests@cff.org prior to submitting their full application to CFF. The formal application
for CFF Patient Registry Data Requests can be found at https://www.cff.org/Research/Researcher-
Resources/Tools-and-Resources/Patient-Registry-Data-Requests/

Note: The application must be submitted using the online system available from the link above and the
e-mail from the system indicating receipt of the application must be uploaded to the submission. Funding
is contingent upon approval to access registry data.

CFF Biorepository Clinical Specimen Confirmation Letter (if applicable)

Since 2006, the Cystic Fibrosis Foundation has collected and stored samples from a variety of clinical trials.
The CF Foundation has developed a database that combines information from these samples with data
from CF clinical trials and the CF Foundation Patient Registry to create a unique and specific sample profile.
To request clinical samples to use in the proposed study, download and complete
the template from https://www.cff.org/Research/Researcher-Resources/Tools-and-Resources/CFFT-
Biorepository/. Applicants must supply a letter from the clinical research program manager confirming
samples are available for their use with their LOI submission. For more information, contact Linh Do, CF
Foundation clinical research program manager, at ldo@cff.org or 301-841-2648.

Note: Applicants must upload the confirmation letter provided by the CFF Clinical Research Program
Manager to the application. Funding is contingent upon approval and availability to access clinical
specimens.

Mentor’s List of Previous Fellows
The current Mentor(s) must provide a list of all previous fellows under his/her supervisions over the past
10 years, including the fellows’ source(s) of support.

Training Plan
The applicant, in conjunction with the Mentor(s) and fellowship program director, should provide a brief
summary of the applicant’s previous research and/or clinical fellowship training, including the reasons for
entering the fields related to CF research and care. In addition, the applicant and Mentor(s) should
develop a training plan that outlines skills and techniques that will be learned during this fellowship period
as well as CF-specific training that will be available to the applicant, including participation in supplemental
course work and special seminars. Further, this section should clearly indicate plans for introducing the
applicant to CF research. This should include training on study planning and design, statistical methods,
data management, etc. This should also include a description of the applicants anticipated CF research.
This plan should address the applicant’s long-term career goals and include training and professional
development activities that will facilitate the applicant’s transition to the next phase of their career. Do
not exceed five (5) pages.

CF-Related Activities of the Mentor and the Applicant Institution
Describe fully the CF related clinical and research activities of the applicant institution. The Mentor and
the applicant institution should also include a list of their previous trainees (past 10 years) and the current
affiliations of these trainees.

Critique Response
If the application is a resubmission, please provide a point-by-point response to the prior reviews. There is
no page limit to your responses, but please be concise and succinct.
Names and Addresses of References
List the names, titles, and contact information of the individuals who have been asked to submit Letters of Support/Reference on the applicant’s behalf. A PDF copy of the completed form should be uploaded.

Appendices (upload as PDF documents)
- Certification of organization assurances (i.e. IRB, IACUC and IBC approvals), if applicable.
- Up to three (3) reprints of the applicant’s work relating to the general area of research in the proposal

*Organization Assurances & Certifications
CFF requires, as applicable, that all U.S.-based awardees obtain Institutional Review Board (IRB) approvals for human subject research, Institutional Biosafety Committee (IBC) approval for recombinant or synthetic nucleic acid research, and Institutional Animal Care and Use Committee (IACUC) approval for animal research, (see additional information regarding these approvals below). Copies of these approvals, if available at the time the application is submitted, must be uploaded with the application as appendices. CFF will not release payments to awardee institutions until these documents are received and on file with the CFF Grants and Contracts Office.

Awardees based outside of the U.S. must comply with the applicable equivalent regulations in their respective countries and provide copies of approvals as soon as they are available. CFF will not release payments until these documents are received and on file with the CFF Grants and Contracts Office.

Research Involving Human Subjects: CFF policy pertaining to the protection of individuals as research subjects requires that for each proposal awarded, the awardee institution certify in writing that an Institutional Review Board (IRB) has reviewed and approved the procedures for the use of human subjects, or human organs, tissues and body fluids, in the proposed research, in accordance with the Department of Health and Human Services policies found at https://www.hhs.gov/ohrp/regulations-and-policy/index.html. In the event the IRB has determined a study is exempt, documentation demonstrating the exempt status must also be submitted to the CFF Grants and Contracts Office.

Research Involving Recombinant or Synthetic Nucleic Acid Molecules: All research involving recombinant or synthetic nucleic acid and human gene transfer studies supported by CFF must meet the requirements contained in the document NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (updated April 2019). This publication and announcements of modifications and changes to the NIH Guidelines are available from the Office of Science and Policy, National Institutes of Health, 6705 Rockledge Drive, Ste 750, MSC 7985, Bethesda, MD, 20892-7985 or online at https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf.

Research Involving Animals: Applications submitted to CFF involving the use of animals must meet the guidelines of the National Institutes of Health found at https://grants.nih.gov/grants/olaw/olaw.htm, which require that all proposed studies be reviewed and approved by an Institutional Animal Care and Use Committee (IACUC). In addition, CFF awardee institutions and laboratories must be accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC) and/or have other verifiable assurances that the institution and laboratory meet appropriate standards.

Validation and Submission
Prior to selecting “Sign & Submit to AIO”, please complete a thorough review of the entire application. The “Sign & Submit to AIO” button will trigger validation on all required fields and identify any upload errors or incomplete fields. Upon submission the ability to edit the application will be locked pending review and approval by your AIO.
Submission by PI and AIO signature and submission should be completed BEFORE the application deadline.

XI. Other Information
   *Not applicable to this RFA*

XII. Contact Information

   **For technical support and program/content information:**
   Primary CFF Grants and Contracts contact Angela Minucci at **aminucci@cff.org** or 301-841-2614

   **For scientific questions:**
   Elizabeth Yu, Ph.D. at **eyu@cff.org**
XIII. Electronic Application Checklist

Application Deadline: Thursday, February 11, 2021 at 5:00 PM (Eastern)

Submit online through: http://awards.cff.org

Face Page which includes:
- Signatures
  - Applicant
    - The Official authorized to sign on behalf of the Applicant Institution
  - Applicant information (online)
- Complete Institution and Applicant Contact Information, including correct mailing address (online)
- Organization Assurances (check those that apply online/complete the required information)
  - Human Subjects Certification
  - Research Involving Recombinant or Synthetic Nucleic Acid Molecules information
  - Research Involving Animals Information

Research Plan & Supporting Documents:
- Biographical Sketches for Key Personnel - (upload)
- Mentor’s Results of Past and Current CFF/CFFT Support - (upload)
- Other Support (NIH Format) - (upload)
- Facilities Available - (upload, if applicable)
- Budget Justification - (upload)
- Research Plan - (upload, if applicable)
  - Hypothesis and Specific Aims
  - Background and Significance
  - Preliminary Results
  - Experimental Design and Methods
  - Literature Cited (not included in Research Plan page limitation)
- Data Safety Monitoring Plan
- Mentor’s List of Previous Fellows - (upload)
- Training Plan - (upload)
- CF-Related Activities of the Mentor and the Applicant Institution – (upload)
- Critique Response – (upload)
- Names and Addresses of References - (upload)
- Appendices (upload, if applicable)
  - Certification of organization assurances (i.e. IRB, IACUC and IBC approvals), if applicable.
  - Up to three (3) reprints of the applicant’s work relating to the general area of research in the proposal